N/A N=12 Transcranial Direct Current Stimulation and Walking in Multiple Sclerosis
Transcranial Direct Current Stimulation
Primary: Distance Walked on a Treadmill With tDCS — 375; 285 m
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=180 W-SUDs for COVID-19
Substance Use Disorders · Alcohol Use Disorder
Primary: Change in Number of Substance Use Occasions in the Past 30 Days From Baseline to Post-treatment at 8 Weeks — -9.1; -4.7 occasions
Phase 2 N=19 Vascular Effects of Mineralocorticoid Receptor Antagonism in Kidney Disease
Chronic Kidney Disease · Albuminuria
Primary: Difference in 24 Hour Ambulatory Systolic Blood Pressure — 7.7; 12.5 mm Hg
N/A N=60 Health Coaching to Improve Self-Management in Thoracic Transplant Candidates
Self-management · Lung Transplant · Heart Transplant
Primary: Score on Follow-up Self-Management Ability Scale (SMAS-30) — 75.06; 71.47 score on a scale
Phase 4 N=20 Angiotensin II in the Perioperative Management of Hypotension in Kidney Transplant Recipients
Shock, Surgical · Shock · Hypotension and Shock
Primary: Duration of ATII Vasopressor Usage in the Intraoperative Setting — 1 hours
N/A N=116 RhinAer Procedure for Treatment of Chronic Rhinitis Study
Chronic Rhinitis
Primary: Reflective Total Nasal Symptom Score (rTNSS) Responder Rate — 52; 16 Participants
N/A N=13 Interactive Rehabilitation for Adults With Unilateral Vestibular Weakness
Dizziness · Equilibrium; Disorder, Labyrinth · Inner Ear Injury
Primary: Change in Sensory Organization Test (SOT) Composite Score (Score After Retraining Minus Score at Baseline) — 8.8 SOT composite score
Phase 3 N=910 Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults
COVID-19
Primary: A Composite of Either Severe COVID-19 or Death From Any Cause Through Day 29 — 18; 37 Participants — p=0.010
Phase 3 N=433 Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis
Ulcerative Colitis
Primary: Percentage of Participants Achieving Clinical Remission at Week 12 — 27.0; 7.4 Percentage of participants — p=<0.001
N/A N=22 Novel MRI Sequence- MR Fingerprinting
Disease
Primary: Percent of Patients With Visible Region of Interest (Imaging Visibility)
N/A N=52 Use of Novel Sinusonic Device for Prevention of Community Acquired Upper Respiratory Infection (URI)
Upper Respiratory Infection
Primary: Total Symptoms Score (TSS) — 0.503; 0.843 scores
Phase 2 N=20 The Role of 68Gallium PSMA-11 in Enhancing Diagnosis of Primary and Metastatic Prostate Cancer
Prostate Cancer · Prostate Cancer Metastatic
Primary: Number of Primary Prostate Lesions Detected on Early Dynamic 68Ga-PSMA-11 PET/CT Imaging — 24 lesions
Phase 3 N=136 Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute Treatment
Binge-eating Disorder · Obesity
Primary: Binge Eating Frequency (Continuous) — 9.90; 7.63; 3.30; 1.97 binge-eating episodes per month — p=0.0001
Phase 2 N=546 Using Biomarkers to Predict TB Treatment Duration
Pulmonary Tuberculosis
Primary: Comparison of the Rate of Treatment Success at 18 Months (After Treatment Initiation) Between Arms B and C — 217; 121; 117; 5 Participants
Phase 3 N=5,197 Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult.
COVID-19
Primary: Number of Participants With First Case of SARS-CoV-2 RT-PCR-positive Symptomatic Illness — 8; 17; 12; 34 Participants — p=<0.001